IL90875A - Pharmaceutical composition for treating viral infection associated chronic fatigue syndrome - Google Patents
Pharmaceutical composition for treating viral infection associated chronic fatigue syndromeInfo
- Publication number
- IL90875A IL90875A IL9087589A IL9087589A IL90875A IL 90875 A IL90875 A IL 90875A IL 9087589 A IL9087589 A IL 9087589A IL 9087589 A IL9087589 A IL 9087589A IL 90875 A IL90875 A IL 90875A
- Authority
- IL
- Israel
- Prior art keywords
- chronic fatigue
- pharmaceutical composition
- fatigue syndrome
- dsrna
- patient
- Prior art date
Links
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title claims abstract description 27
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 208000036142 Viral infection Diseases 0.000 title claims description 6
- 230000009385 viral infection Effects 0.000 title claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 30
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 29
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 8
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
- 229940035893 uracil Drugs 0.000 claims description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 231100001274 therapeutic index Toxicity 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 8
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 6
- 230000002093 peripheral effect Effects 0.000 abstract description 2
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 14
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 14
- 102000003960 Ligases Human genes 0.000 description 10
- 108090000364 Ligases Proteins 0.000 description 10
- 206010016256 fatigue Diseases 0.000 description 8
- 230000004075 alteration Effects 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000003990 molecular pathway Effects 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000009483 enzymatic pathway Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 1
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 1
- -1 AMPLIGEN® Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241001399969 Syntheta Species 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000009110 definitive therapy Methods 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000011987 exercise tolerance test Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL10822793A IL108227A0 (en) | 1988-07-07 | 1993-12-29 | In vitro method for diagnosis of chronic viral infection and viral-induced chronic fatigue syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22076588A | 1988-07-07 | 1988-07-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL90875A0 IL90875A0 (en) | 1990-02-09 |
| IL90875A true IL90875A (en) | 1994-04-12 |
Family
ID=22824871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9087589A IL90875A (en) | 1988-07-07 | 1989-07-05 | Pharmaceutical composition for treating viral infection associated chronic fatigue syndrome |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0350151B1 (pt) |
| CN (1) | CN1056747C (pt) |
| AT (1) | ATE103493T1 (pt) |
| AU (2) | AU3781189A (pt) |
| CA (1) | CA1336685C (pt) |
| DE (1) | DE68914201T2 (pt) |
| DK (1) | DK332289A (pt) |
| ES (2) | ES2066847T3 (pt) |
| IE (1) | IE63927B1 (pt) |
| IL (1) | IL90875A (pt) |
| NZ (1) | NZ229849A (pt) |
| PT (1) | PT91094B (pt) |
| ZA (1) | ZA895143B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT65370A (en) * | 1989-10-16 | 1994-05-02 | Hem Res Inc | Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction |
| GB9108085D0 (en) * | 1991-04-16 | 1991-06-05 | Scras | Complexes of polyadenylic acid with polyuridylic acid |
| US5776690A (en) * | 1996-10-07 | 1998-07-07 | Vojdani; Aristo | Detection of chronic fatigue syndrome by decreased levels of RNase L inhibitor mRNA |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| WO1999049029A1 (en) | 1998-03-20 | 1999-09-30 | Benitec Australia Ltd | Control of gene expression |
| EP1147204A1 (en) | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
| CA2369944A1 (en) | 2001-01-31 | 2002-07-31 | Nucleonics Inc. | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| WO2010104571A2 (en) * | 2009-03-13 | 2010-09-16 | Hemispherx Biopharma, Inc. | Treating chronic fatigue syndrome and prolonged qt interval |
| EP3652542A1 (en) * | 2017-07-14 | 2020-05-20 | Protea Biopharma N.V. | Methods and means for diagnosing and/or treating a fatiguing illness |
| EP3893893A1 (en) * | 2018-12-13 | 2021-10-20 | Aim Immunotech Inc. | Methods for improving exercise tolerance in myalgic encephalomyelitis patients |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1326450C (en) * | 1985-08-26 | 1994-01-25 | William A. Carter | Modulation of aids virus-related events by double stranded rnas (dsrnas) |
| PH30882A (en) * | 1987-03-03 | 1997-12-23 | Hem Res Inc | Activated Rnase L as a maker for viral infections. |
| AU1820388A (en) * | 1987-07-17 | 1989-01-19 | Hem Research, Inc. | Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles |
| EP0306347B1 (en) * | 1987-09-04 | 1995-05-10 | Hem Pharmaceuticals Corp. | Diagnosis of double-stranded RNA deficiency states |
-
1989
- 1989-04-26 EP EP89304188A patent/EP0350151B1/en not_active Expired - Lifetime
- 1989-04-26 AT AT89304188T patent/ATE103493T1/de not_active IP Right Cessation
- 1989-04-26 ES ES89304188T patent/ES2066847T3/es not_active Expired - Lifetime
- 1989-04-26 DE DE68914201T patent/DE68914201T2/de not_active Expired - Fee Related
- 1989-06-30 CA CA000604511A patent/CA1336685C/en not_active Expired - Fee Related
- 1989-07-04 DK DK332289A patent/DK332289A/da not_active Application Discontinuation
- 1989-07-04 AU AU37811/89A patent/AU3781189A/en not_active Abandoned
- 1989-07-05 IL IL9087589A patent/IL90875A/en not_active IP Right Cessation
- 1989-07-06 IE IE218089A patent/IE63927B1/en not_active IP Right Cessation
- 1989-07-06 ES ES8902387A patent/ES2018903A6/es not_active Expired - Fee Related
- 1989-07-06 ZA ZA895143A patent/ZA895143B/xx unknown
- 1989-07-06 NZ NZ229849A patent/NZ229849A/en unknown
- 1989-07-07 CN CN89106706A patent/CN1056747C/zh not_active Expired - Fee Related
- 1989-07-07 PT PT91094A patent/PT91094B/pt not_active IP Right Cessation
-
1994
- 1994-08-02 AU AU68836/94A patent/AU684288B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE68914201T2 (de) | 1994-07-14 |
| ES2066847T3 (es) | 1995-03-16 |
| PT91094B (pt) | 1995-01-31 |
| NZ229849A (en) | 1997-07-27 |
| ATE103493T1 (de) | 1994-04-15 |
| AU6883694A (en) | 1994-11-24 |
| ES2018903A6 (es) | 1991-05-16 |
| DK332289A (da) | 1990-01-08 |
| IE892180L (en) | 1990-01-07 |
| EP0350151A2 (en) | 1990-01-10 |
| PT91094A (pt) | 1990-02-08 |
| IE63927B1 (en) | 1995-06-28 |
| DE68914201D1 (de) | 1994-05-05 |
| EP0350151A3 (en) | 1990-10-03 |
| EP0350151B1 (en) | 1994-03-30 |
| DK332289D0 (da) | 1989-07-04 |
| IL90875A0 (en) | 1990-02-09 |
| CN1039722A (zh) | 1990-02-21 |
| AU684288B2 (en) | 1997-12-11 |
| ZA895143B (en) | 1991-04-24 |
| CA1336685C (en) | 1995-08-15 |
| CN1056747C (zh) | 2000-09-27 |
| AU3781189A (en) | 1990-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6130206A (en) | Treating viral infections associated with chronic fatigue with dsRNA | |
| Gilchrist et al. | Clinical and genetic investigation in autosomal dominant limb‐girdle muscular dystrophy | |
| Bolton | Neuromuscular manifestations of critical illness | |
| Spitsin et al. | Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease | |
| AU684288B2 (en) | Diagnosing and treating chronic fatigue syndrome | |
| Tzanakis et al. | Lung function in patients with inflammatory bowel disease | |
| Kadashetti et al. | Glucose level estimation in diabetes mellitus by saliva: a bloodless revolution | |
| Wilkinson et al. | The response to treatment of subclinical thiamine deficiency in the elderly | |
| McHardy-Young et al. | Singledose dexamethasone suppression test for Cushing's Syndrome | |
| O’Donnell et al. | Neurosyphilis: a current review | |
| WO1991000097A1 (en) | Diagnosing and treating viral infections associated with chronic fatigue | |
| Kagen et al. | Serum myoglobin in muscular dystrophy | |
| US5958718A (en) | Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction | |
| Peterson et al. | Correlation of self-administered alcoholism screening test with hemoglobin-associated acetaldehyde | |
| JP7383259B2 (ja) | Ｓｇｌｔ２阻害薬の感受性の判定方法及びｓｇｌｔ２阻害薬に対する感受性マーカー | |
| Koren et al. | Uptake of serotonin into platelets of senile dementia of the Alzheimer type patients | |
| Quinn et al. | False positive diagnosis of phaeochromocytoma in a patient with Parkinson's disease receiving levodopa | |
| Wassif et al. | Use of dynamic tests of muscle function and histomorphometry of quadriceps muscle biopsies in the investigation of patients with chronic alcohol misuse and chronic fatigue syndrome | |
| Johns et al. | Hereditary optic neuropathies | |
| Şenol et al. | Plasma apelin levels in diabetic patients with and without neuropathy | |
| JPWO2020080491A1 (ja) | 血液中のクレアチニン量に基づく腎機能検査結果の妥当性を検定する方法 | |
| Altaweel et al. | Ocular and systemic safety evaluation of calcium formate as a dietary supplement | |
| Wojnar et al. | Extent of interocular (a) symmetry based on the metabolomic profile | |
| Makkar et al. | A study of clinical profile and spontaneous course of eosinophilia | |
| Winkler et al. | Effects of oxidized glutathione on ATPase activities in rat retina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees | ||
| KB | Patent renewed |